New Delhi: Union health minister, Harsh Vardhan, said that Serum Institute of India has been manufacturing an intranasal vaccine candidate as there is no such candidate under trial even when there are 3 vaccines of COVID-19 being tested on humans in India.
“Flumist nasal spray is a vaccine that is sprayed into the nose to help protest against influenza; it is not a COVID-19 vaccine. At present in India, there is no intranasal COVID vaccine which is under clinical trials. However, Serum Institute (of India) has begun manufacturing Codagenix CDX 005, which is an intranasal live attenuated vaccine candidate for Sars-Cov-2”, he said.
“Pre clinical animal studies have already been completed and Codagenix expects to initiate a phase 1 clinical first in humans trial in the United Kingdom by the end of 2020.Further, Serum India plans to undertake clinical developments of this vaccine candidate in India”.
India’s Bharat Biotech entered in an agreement with Washington University School of medicine as part of it is supposed to conduct trials to produce an intranasal vaccine for COVID-19.
“The phase 1 trials will take place in the US in St. Louis University’s vaccine and treatment evaluation unit, on getting regulatory approval, Bharat Biotech will pursue further stages of clinical trials in India”, he said.
The minister also said that Bharat Biotech’s vaccines were tested on people between 18 and 55 years in phase 1, and was extended to ages between 12 and 65 years in phase 2.